Medexus Pharmaceuticals Inc.

Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Medexus Schedules Third Fiscal Quarter 2026 Conference Call

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares